Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to ...

Nektar is on track to announce topline results from its Phase 2b trials for REZPEG in atopic dermatitis and alopecia areata in June and December 2025, respectively.

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 ...

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotech with a market capitalization of $119 million, will host an investor call tomorrow to present top-line data from the 16-week ...

Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic ...

An analyst tracking the stock made a drastic change to his price target. The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock ...

The latest biotech stock to explode in price, Nektar Therapeutics (NKTR 1.20%) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering ...